Access the full text.
Sign up today, get DeepDyve free for 14 days.
Code of federal regulations, title 21 food and drugs, subchapter D drugs for human use, part 312, subpart B investigational new drug application
Andrew Wang, R. Langer, O. Farokhzad (2012)
Nanoparticle delivery of cancer drugs.Annual review of medicine, 63
(2010)
Box 2.30: Suggested Resources Reviews
C. King, N. Sarvetnick (2011)
The Incidence of Type-1 Diabetes in NOD Mice Is Modulated by Restricted Flora Not Germ-Free ConditionsPLoS ONE, 6
R. Rydzewski (2008)
Real World Drug Discovery: A Chemist's Guide to Biotech and Pharmaceutical Research
R. Kneller (2010)
The importance of new companies for drug discovery: origins of a decade of new drugsNature Reviews Drug Discovery, 9
(1997)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdv Drug Delivery Rev, 23
F. Prinz, T. Schlange, K. Asadullah (2011)
Believe it or not: how much can we rely on published data on potential drug targets?Nature Reviews Drug Discovery, 10
R. Copeland (2003)
Mechanistic considerations in high-throughput screening.Analytical biochemistry, 320 1
C. Begley, Lee Ellis (2012)
Raise standards for preclinical cancer research
C. Begley (2013)
Reproducibility: Six red flags for suspect workNature, 497
(2010)
The importance of new companies for drug discovery: origins of a decade of new drugsNat Rev Drug Discov, 9
F. Collins (2011)
Reengineering Translational Science: The Time Is RightScience Translational Medicine, 3
William Liechty, David Kryscio, B. Slaughter, N. Peppas (2010)
Polymers for drug delivery systems.Annual review of chemical and biomolecular engineering, 1
Ruili Huang, Noel Southall, Yuhong Wang, Adam Yasgar, P. Shinn, A. Jadhav, Dac-Trung Nguyen, C. Austin (2011)
The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical GenomicsScience Translational Medicine, 3
I. Peers, P. Ceuppens, C. Harbron (2012)
In search of preclinical robustnessNature Reviews Drug Discovery, 11
Ge Wu, Yue Yuan, C. Hodge (2003)
Determining Appropriate Substrate Conversion for Enzymatic Assays in High-Throughput ScreeningJournal of Biomolecular Screening, 8
M. Ekroos, T. Sjögren (2006)
Structural basis for ligand promiscuity in cytochrome P450 3A4Proceedings of the National Academy of Sciences, 103
C. Begley, Lee Ellis (2012)
Drug development: Raise standards for preclinical cancer researchNature, 483
Christopher, A. Lipinski, Beryl, W. Dominy, Paul, J. Feeney (2001)
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Advanced drug delivery reviews, 46 1-3
Ji-Hu Zhang, T. Chung, K. Oldenburg (1999)
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening AssaysJournal of Biomolecular Screening, 4
J. Arrowsmith (2011)
Trial watch: Phase II failures: 2008–2010Nature Reviews Drug Discovery, 10
[In any drug discovery and development effort, we must accomplish a number of critical steps to arrive at a compound that is safe and efficacious, and also exhibits the complex array of desired drug-like behaviors that warrants advancement to the clinic. These tasks include target identification and validation; screening for active compounds; chemical modification of candidate compounds to achieve optimized pharmacology; formulating the final drug product; and establishing safety in preclinical models. “Repurposing” drugs that have previously been approved (or shown to be safe in humans) for new clinical indications can provide a faster, less risky, and more cost-effective route for bringing a new therapy to patients. Such shortcuts in development can be particularly valuable to resource-constrained academicians. When performing drug discovery research, we must be particularly attentive to the robustness of our experiments, because inability to reproduce academic data continues to be a sticking point when projects are transferred to industry. Our experiments must be appropriately blinded, statistically powered, and meticulously documented so that our findings are worthy of the large investment required for their further translation into a drug. This chapter walks through the essential preclinical drug development steps that lead to a clinical drug candidate.]
Published: Sep 23, 2013
Keywords: Active Pharmaceutical Ingredient; Lead Optimization; ADME Property; Secondary Assay; Preclinical Safety Study
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.